3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
84
Breast Neoplasms
10
Neoplasm Metastasis
7
Neoplasms
5
Prostatic Neoplasms, Castration-Resistant
4
Prostate Cancer Metastatic
4
Metastatic Castration-Resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
3
Castration-resistant Prostate Cancer
3
Triple Negative Breast Neoplasms
2
Castration Resistant Metastatic Prostate Cancer
2
Adenocarcinoma of the Prostate
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Primary Breast Cancer ER+ve
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoadjuvant Therapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Metastatic Hormone-sensitive Prostate Cancer
1
Interventions
Carboplatin
36
Pemetrexed
28
Bevacizumab
26
Cisplatin
24
Paclitaxel
22
Gemcitabine
20
Radiotherapy
18
Docetaxel
18
Erlotinib Hydrochloride
15
Gefitinib
11
pembrolizumab
6
Cetuximab
6
capmatinib
5
Surgical Procedures, Operative
5
Radiosurgery
5
aflutinib
4
Vinorelbine
4
Taxes
4
Platinum
4
Nivolumab
4
Metformin
4
pegfilgrastim
3
durvalumab
3
ceritinib
3
apatinib
3
Sorafenib
3
Radiation
3
Neoadjuvant Therapy
3
Magnetic Resonance Spectroscopy
3
tislelizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma of Lung
×
enzalutamide
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled